Quantcast
Last updated on April 23, 2014 at 20:00 EDT

Latest United Therapeutics Corporation Stories

2014-04-22 08:32:17

SILVER SPRING, Md., April 22, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its first quarter 2014 financial results before market open on Tuesday, April 29, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, April 29, 2014, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will...

2014-03-26 08:28:21

SILVER SPRING, Md., March 26, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin(®) (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost(TM) by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with...

2014-02-25 08:30:36

SILVER SPRING, Md., Feb. 25, 2014 /PRNewswire/ -- -- Total Annual Revenues of $1.1 billion -- Annual Earnings per Share of $3.49 per Basic Share or $3.28 per Diluted Share -- Annual Non-GAAP Earnings of $10.88 per Basic Share or $10.23 per Diluted Share United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2013. "United Therapeutics continued to deliver strong results in 2013,...

2014-02-18 08:29:26

SILVER SPRING, Md., Feb. 18, 2014 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its fourth quarter and annual 2013 financial results before market open on Tuesday, February 25, 2014. United Therapeutics will host a half-hour teleconference on Tuesday, February 25, 2014, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the...

2013-12-20 20:21:16

Conference Call to be Held at 9:00 a.m. Eastern Time, December 23, 2013 SILVER SPRING, Md., Dec. 20, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the United States Food and Drug Administration (FDA) has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension (PAH) in WHO Group I patients to improve exercise capacity. "This approval marks the first time that the FDA has approved an orally...

2013-12-09 08:27:05

SILVER SPRING, Md., Dec. 9, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it has received a subpoena from the Office of the Inspector General of the Department of Health and Human Services reflecting an investigation by the United States Department of Justice, principally represented by the United States Attorney's Office in Baltimore. The subpoena requests documents regarding Remodulin® (treprostinil) Injection, Tyvaso® (treprostinil)...

2013-10-29 08:31:07

SILVER SPRING, Md., Oct. 29, 2013 /PRNewswire/ -- -- Revenues of $302.2 million -- Earnings per Share of $1.25 per Basic Share or $1.17 per Diluted Share -- Non-GAAP Earnings of $2.98 per Basic Share or $2.78 per Diluted Share -- Raising Revenue Guidance for 2013 to Above $1.05 billion United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2013. "I am extremely pleased with the results of the third...

2013-10-22 08:31:45

SILVER SPRING, Md., Oct. 22, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will release its third quarter 2013 financial results before market open on Tuesday, October 29, 2013. United Therapeutics will host a half-hour teleconference on Tuesday, October 29, 2013, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference...

2013-09-11 16:25:31

SILVER SPRING, Md., Sept. 11, 2013 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 2 response to its March 22, 2013 complete response letter, and set a...

2013-07-29 12:26:17

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 29, 2013 /PRNewswire/ -- On Friday, July 26, 2013, shares of drug manufacturers ended mostly lower even as the broader market posted small gains. The major movers in the sector included United Therapeutics Corporation (NASDAQ: UTHR), Pharmacyclics, Inc. (NASDAQ: PCYC), Star Scientific, Inc. (NASDAQ: STSI), and Impax Laboratories Inc. (NASDAQ: IPXL). All these companies are tracked by...